Specific treatment of menopausal disorders in perimenopausal women

The sharp increase in morbidity among women of perimenopausal age often leads to a decrease in labor productivity and social maladjustment of women. This problem is of particular relevance in Ukraine, where women over 50 years old make up the majority of the female population. That is why the treatment of climacteric disorders is of particular importance.The objective: to study the efficacy and safety of the drug (Lachesis 30CH 20 mg, Sanguinaria canadensis 30CH 20 mg, Glonoinum 200CH 20 mg, Cimicifuga 200CH 20 mg, Sulfur 30CH 20 mg) in patients with mild and moderate menopausal disorders in the late reproductive period.Materials and methods. 60 patients aged 37–52 years with menopausal disorders were examined. To determine the severi­ty of symptoms, the international scale for assessing menopause symptoms (Menopause Rating Scale – MRS) was used. For correction of climacteric disorders, a drug was prescribed (Lachesis 30CH 20 mg, Sanguinaria canadensis 30CH 20 mg, Glonoinum 200CH 20 mg, Cimicifuga 200CH 20 mg, Sulfur 30CH 20 mg) for 3 months. The effectiveness of the treatment was assessed by studying the dynamics of climacteric symptoms, levels of follicle-stimulating, luteinizing hormones, estradiol, prolactin, progesterone, as well as by liver biochemical results before the start of treatment and after 3 months of therapy. Ultrasound examination of the pelvic organs at the screening stage, 1 and 3 months of drug therapy to monitor the safety of the endometrium was used.Results. After the therapy, the average menopausal index, according to the MRS, was significantly lower (8.7 ± 0.2 points) than before the start of therapy (24.02 ± 0.80 points). After 3 months of treatment with the drug (Lachesis 30CH 20 mg, Sanguina­ria canadensis 30CH 20 mg, Glonoinum 200CH 20 mg, Cimicifuga 200CH 20 mg, Sulfur 30CH 20 mg) in all examined women, hormone levels corresponded to perimenopausal values. No side effects and individual intolerance reactions were registered.Conclusions. The results obtained indicate the feasibility of using drug (Lachesis 30CH 20 mg, Sanguinaria canadensis 30CH 20 mg, Glonoinum 200CH 20 mg, Cimicifuga 200CH 20 mg, Sulfur 30CH 20 mg) in women of late reproductive age for the treatment of mild and moderate menopausal disorders.